Summary & Overview
HCPCS G0429: Dermal Filler Injection for Facial Lipodystrophy Syndrome
HCPCS Level II code G0429 represents dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (LDS), a condition often seen in patients receiving highly active antiretroviral therapy. Nationally, this code identifies outpatient procedures intended to restore facial soft-tissue volume for functional and reconstructive purposes related to LDS. Use of G0429 matters for payers and providers because it distinguishes reconstructive filler treatment for a recognized syndrome from cosmetic-only interventions, influencing coverage considerations and claims adjudication.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise guide to what G0429 denotes clinically and operationally, plus an overview of payer coverage patterns and billing considerations. The publication outlines typical sites of service, common modifiers (listed separately), and areas where policy updates or clarifications commonly arise for injectable dermal filler services for LDS.
This summary equips billing, coding, and compliance teams with a clear understanding of the code’s clinical intent, the typical outpatient service setting, and the payer landscape to inform documentation, claim submission, and policy review. Data not available in the input is noted where applicable in detailed sections of the publication.
Billing Code Overview
HCPCS Level II code G0429 describes dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (LDS), for example when associated with highly active antiretroviral therapy. The service is a cosmetic/reconstructive soft-tissue augmentation using injectable dermal fillers to restore facial volume lost from lipodystrophy. The typical site of service is an outpatient or ambulatory care setting such as a dermatology clinic, plastic surgery clinic, or other outpatient procedural suite where minimally invasive aesthetic or reconstructive injections are performed.
Clinical & Coding Specifications
Clinical Context
A 45-year-old patient with a history of HIV on long-term antiretroviral therapy presents to a dermatology/plastic surgery clinic with progressive facial lipoatrophy (facial lipodystrophy syndrome) causing marked midface contour loss and psychosocial distress. After evaluation by the treating physician, conservative measures are discussed and the patient elects for dermal filler injections to restore facial volume. The clinical workflow includes: pre-procedure assessment and medical history review (including anticoagulant use and active infection), informed consent, documentation of baseline photographs, marking of treatment areas, aseptic preparation, administration of local anesthetic as needed, staged injections of appropriate FDA-cleared dermal filler products into the subcutaneous and/ or supraperiosteal planes to correct volume deficits, post-injection instructions, and scheduled follow-up for outcome assessment and possible touch-up treatments. Billing is submitted using G0429 for dermal filler injection(s) specifically for treatment of facial lipodystrophy syndrome; appropriate modifiers are appended as indicated by encounter circumstances (e.g., bilateral services, unrelated E/M visit on same day, reduced services, unusual procedural circumstances). Typical sites of service are outpatient dermatology or plastic surgery clinics and ambulatory surgical centers where injectable soft-tissue augmentation is performed under local anesthesia.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 |